HRP20161458T1 - Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze - Google Patents

Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze Download PDF

Info

Publication number
HRP20161458T1
HRP20161458T1 HRP20161458TT HRP20161458T HRP20161458T1 HR P20161458 T1 HRP20161458 T1 HR P20161458T1 HR P20161458T T HRP20161458T T HR P20161458TT HR P20161458 T HRP20161458 T HR P20161458T HR P20161458 T1 HRP20161458 T1 HR P20161458T1
Authority
HR
Croatia
Prior art keywords
seq
rv3616c protein
sequence
polypeptide
variant
Prior art date
Application number
HRP20161458TT
Other languages
English (en)
Croatian (hr)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20161458T1 publication Critical patent/HRP20161458T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HRP20161458TT 2008-07-25 2009-07-24 Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze HRP20161458T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods
EP09781052.7A EP2315773B1 (en) 2008-07-25 2009-07-24 Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis

Publications (1)

Publication Number Publication Date
HRP20161458T1 true HRP20161458T1 (hr) 2016-12-16

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161458TT HRP20161458T1 (hr) 2008-07-25 2009-07-24 Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze

Country Status (24)

Country Link
US (2) US20110117119A1 (cg-RX-API-DMAC7.html)
EP (1) EP2315773B1 (cg-RX-API-DMAC7.html)
JP (1) JP5873332B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110044883A (cg-RX-API-DMAC7.html)
CN (1) CN102164952B (cg-RX-API-DMAC7.html)
AU (1) AU2009273130B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2731499C (cg-RX-API-DMAC7.html)
CO (1) CO6341637A2 (cg-RX-API-DMAC7.html)
CY (1) CY1118200T1 (cg-RX-API-DMAC7.html)
DK (1) DK2315773T3 (cg-RX-API-DMAC7.html)
EA (1) EA024826B1 (cg-RX-API-DMAC7.html)
ES (1) ES2602430T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161458T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031044T2 (cg-RX-API-DMAC7.html)
IL (1) IL210559A0 (cg-RX-API-DMAC7.html)
LT (1) LT2315773T (cg-RX-API-DMAC7.html)
MX (1) MX2011000983A (cg-RX-API-DMAC7.html)
PL (1) PL2315773T3 (cg-RX-API-DMAC7.html)
PT (1) PT2315773T (cg-RX-API-DMAC7.html)
SG (1) SG192456A1 (cg-RX-API-DMAC7.html)
SI (1) SI2315773T1 (cg-RX-API-DMAC7.html)
UA (1) UA107330C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010010177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026248A2 (en) * 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
LT2315834T (lt) 2008-07-25 2018-09-10 Glaxosmithkline Biologicals S.A. Tuberkuliozės rv2386c baltymas, kompozicijos ir jų panaudojimas
ES2647321T3 (es) 2008-07-25 2017-12-20 Glaxosmithkline Biologicals S.A. Composiciones y procedimientos novedosos
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
HRP20161608T1 (hr) * 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
JP6857029B2 (ja) 2013-09-27 2021-04-14 コデクシス, インコーポレイテッド 酵素バリアントの自動スクリーニング
HUE048104T2 (hu) * 2013-09-27 2020-05-28 Codexis Inc Szerkezet alapú prediktív modellezés
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CA3252762A1 (en) 2019-04-12 2025-07-08 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CN1163602C (zh) * 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
DK2133100T3 (da) * 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
CZ20031866A3 (cs) * 2001-01-08 2004-03-17 Isis Innovation Limited Způsob pro stanovení účinnosti léčení mykobakteriální infekce
CN1277843C (zh) * 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
EP2457926B1 (en) 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
EP2380589A3 (en) * 2005-06-23 2012-09-12 Statens Serum Institut Improved tuberculosis vaccines
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
HRP20161608T1 (hr) 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni

Also Published As

Publication number Publication date
IL210559A0 (en) 2011-03-31
AU2009273130B2 (en) 2014-10-16
HUE031044T2 (en) 2017-06-28
CN102164952A (zh) 2011-08-24
PL2315773T3 (pl) 2017-07-31
ES2602430T3 (es) 2017-02-21
CO6341637A2 (es) 2011-11-21
AU2009273130A1 (en) 2010-01-28
UA107330C2 (uk) 2014-12-25
SG192456A1 (en) 2013-08-30
EP2315773B1 (en) 2016-08-24
EA201100072A1 (ru) 2011-10-31
DK2315773T3 (en) 2016-12-12
CA2731499A1 (en) 2010-01-28
CY1118200T1 (el) 2017-06-28
JP2011528895A (ja) 2011-12-01
US20110117119A1 (en) 2011-05-19
CN102164952B (zh) 2016-05-25
EA024826B1 (ru) 2016-10-31
LT2315773T (lt) 2016-11-10
KR20110044883A (ko) 2011-05-02
BRPI0916703A2 (pt) 2019-12-24
PT2315773T (pt) 2016-11-23
MX2011000983A (es) 2011-03-02
EP2315773A1 (en) 2011-05-04
SI2315773T1 (sl) 2016-12-30
US20140178423A1 (en) 2014-06-26
WO2010010177A1 (en) 2010-01-28
JP5873332B2 (ja) 2016-03-01
US9795663B2 (en) 2017-10-24
CA2731499C (en) 2017-01-10

Similar Documents

Publication Publication Date Title
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
JP2011528896A5 (cg-RX-API-DMAC7.html)
JP2015514132A5 (cg-RX-API-DMAC7.html)
JP2011528895A5 (cg-RX-API-DMAC7.html)
JP2006506942A5 (cg-RX-API-DMAC7.html)
JP2011528897A5 (cg-RX-API-DMAC7.html)
HRP20141233T1 (hr) PEPTIDNA CJEPIVA DOBIVENA IZ EphA4
JP2010519176A5 (cg-RX-API-DMAC7.html)
HRP20161608T1 (hr) Modificirani tuberkulozni antigeni
JP2010506826A5 (cg-RX-API-DMAC7.html)
HRP20161305T1 (hr) Liječenje mikrobnih infekcija
JP2015525217A5 (cg-RX-API-DMAC7.html)
JP2008529558A5 (cg-RX-API-DMAC7.html)
ATE462003T1 (de) Aus wt1 stammende krebsantigenpeptide
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
JP2008530245A5 (cg-RX-API-DMAC7.html)
JP2007529204A5 (cg-RX-API-DMAC7.html)
JP2019525753A5 (cg-RX-API-DMAC7.html)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2014529399A5 (cg-RX-API-DMAC7.html)
JP2008521795A5 (cg-RX-API-DMAC7.html)
JP2017536124A5 (cg-RX-API-DMAC7.html)
JP2009527510A5 (cg-RX-API-DMAC7.html)
JP2009544304A5 (cg-RX-API-DMAC7.html)
JP2020117504A5 (cg-RX-API-DMAC7.html)